In Brief: Ketoprofen Rx-to-OTC switches
This article was originally published in The Tan Sheet
Executive Summary
Ketoprofen Rx-to-OTC switches: FDA informed Bayer and Whitehall-Robins on July 19 that their respective Rx-to-OTC switch applications for nonsteroidal anti-inflammatory drug ketoprofen are "approvable." The letters were sent less than a week after FDA's Nonprescription Drugs and Arthritis Advisory Committees recommended approval of the switches ("The Tan Sheet" July 17, pp. 1-3)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning